Implementation of phosphoprotein preservation technology for cancer biospecimens View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2011-2016

FUNDING AMOUNT

922109 USD

ABSTRACT

DESCRIPTION (provided by applicant): An urgent clinical goal is to identify molecular networks associated with subpopulations of cancer patients who may respond individually to molecular targeted inhibitors. Current molecular targeted therapeutics is directed at protein kinases and/or their phosphorylated substrates. Therefore, measurement of this new class of phosphoprotein signal pathway epitopes in tumor biopsy samples is crucial for individualizing molecular targeted therapies. Phosphoprotein antigen epitopes are not adequately preserved by formalin fixation and paraffin embedding, and freezing of tissue is very expensive and compromises diagnostic accuracy. We propose the advanced development and clinical validation of an innovative and transformative technology for preserving tissue phosphoproteins and diagnostic histomorphology for clinical cancer molecular profiling. Applying knowledge gained under an NIH R21 funded study, we created a novel tissue preservation chemistry that stabilizes all classes of phosphoproteins, is compatible with paraffin embedding, while maintaining complete diagnostic histomorphology, and fully preserving critical diagnostic immunohistology (IHC) antigens including Estrogen Receptor, Progesterone Receptor, HER2, and Ki-67. These IHC antigens are not preserved by special research fixatives used for tissue RNA preservation. Our new non-formalin tissue preservative, termed Biomarker and Histology Preservative (BHP) can be seamlessly introduced into the current community hospital clinical diagnostic workflow with no additional steps or equipment. At the time of procurement, tissue can be immersed directly in the new fixative and processed into a paraffin block for routine diagnosis, obviating the need for costly freezing during shipping or storage. BHP offers the potential for substantial improvements over conventional formalin fixation. In the present application we propose the blinded clinical validation of our novel preservation chemistry in community hospital settings, utilizing a team of international pathologists for validation. The goal of the project is one-step paraffin block stabilization of all classes of cellular phosphoproteins, diagnostic histomorphology, and diagnostic immunohistochemistry antigens, while at the same time maintaining full diagnostic morphology equivalent or superior to standard formalin fixation. We will collect fresh surgical tissue, under informed consent, covering a broad variety of organs and cancer histology to develop an archive of 150 cases of matched paraffin and frozen specimens. We will measure 100 validated phosphoprotein epitopes spanning membrane, cytoplasmic and nuclear compartments from extracted paraffin sections using Reverse Phase Protein Microarray (RPMA) and Laser Capture Microdissection (LCM) technology. Following objective independent validation by diagnostic pathologists, this transformative technology will be ready for widespread clinical and research use. Adoption of the technology would mean that only one diagnostic paraffin block could be used for all classes of molecular profiling rather than the current requirement for multiple blocks. This would increase diagnostic accuracy while substantially reducing costs. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=8504815

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2206", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "922109"
    }, 
    "description": "DESCRIPTION (provided by applicant): An urgent clinical goal is to identify molecular networks associated with subpopulations of cancer patients who may respond individually to molecular targeted inhibitors. Current molecular targeted therapeutics is directed at protein kinases and/or their phosphorylated substrates. Therefore, measurement of this new class of phosphoprotein signal pathway epitopes in tumor biopsy samples is crucial for individualizing molecular targeted therapies. Phosphoprotein antigen epitopes are not adequately preserved by formalin fixation and paraffin embedding, and freezing of tissue is very expensive and compromises diagnostic accuracy. We propose the advanced development and clinical validation of an innovative and transformative technology for preserving tissue phosphoproteins and diagnostic histomorphology for clinical cancer molecular profiling. Applying knowledge gained under an NIH R21 funded study, we created a novel tissue preservation chemistry that stabilizes all classes of phosphoproteins, is compatible with paraffin embedding, while maintaining complete diagnostic histomorphology, and fully preserving critical diagnostic immunohistology (IHC) antigens including Estrogen Receptor, Progesterone Receptor, HER2, and Ki-67. These IHC antigens are not preserved by special research fixatives used for tissue RNA preservation. Our new non-formalin tissue preservative, termed Biomarker and Histology Preservative (BHP) can be seamlessly introduced into the current community hospital clinical diagnostic workflow with no additional steps or equipment. At the time of procurement, tissue can be immersed directly in the new fixative and processed into a paraffin block for routine diagnosis, obviating the need for costly freezing during shipping or storage. BHP offers the potential for substantial improvements over conventional formalin fixation. In the present application we propose the blinded clinical validation of our novel preservation chemistry in community hospital settings, utilizing a team of international pathologists for validation. The goal of the project is one-step paraffin block stabilization of all classes of cellular phosphoproteins, diagnostic histomorphology, and diagnostic immunohistochemistry antigens, while at the same time maintaining full diagnostic morphology equivalent or superior to standard formalin fixation. We will collect fresh surgical tissue, under informed consent, covering a broad variety of organs and cancer histology to develop an archive of 150 cases of matched paraffin and frozen specimens. We will measure 100 validated phosphoprotein epitopes spanning membrane, cytoplasmic and nuclear compartments from extracted paraffin sections using Reverse Phase Protein Microarray (RPMA) and Laser Capture Microdissection (LCM) technology. Following objective independent validation by diagnostic pathologists, this transformative technology will be ready for widespread clinical and research use. Adoption of the technology would mean that only one diagnostic paraffin block could be used for all classes of molecular profiling rather than the current requirement for multiple blocks. This would increase diagnostic accuracy while substantially reducing costs.", 
    "endDate": "2016-07-31T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.48336.3a", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2631858", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2631858"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "R33CA157403"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "equipment", 
      "inhibitors", 
      "phosphoprotein", 
      "multiple blocks", 
      "clinical cancer molecular profiling", 
      "diagnostic accuracy", 
      "diagnostic paraffin block", 
      "cytoplasmic", 
      "membrane", 
      "diagnostic pathologist", 
      "phosphoprotein signal pathway epitopes", 
      "special research fixatives", 
      "international pathologists", 
      "IHC", 
      "archives", 
      "class", 
      "knowledge", 
      "implementation", 
      "laser capture microdissection", 
      "team", 
      "clinical diagnostic workflow", 
      "measurements", 
      "tissue RNA preservation", 
      "therapy", 
      "current community hospital", 
      "cancer biospecimens", 
      "compromise", 
      "one-step paraffin block stabilization", 
      "cancer patients", 
      "Phosphoprotein antigen epitopes", 
      "critical diagnostic immunohistology", 
      "broad variety", 
      "research use", 
      "tissue phosphoproteins", 
      "shipping", 
      "antigen", 
      "phosphorylated substrates", 
      "phosphoprotein preservation technology", 
      "adoption", 
      "paraffin embedding", 
      "informed consent", 
      "cellular phosphoproteins", 
      "community hospital settings", 
      "blinded clinical validation", 
      "paraffin sections", 
      "phosphoprotein epitopes", 
      "goal", 
      "same time", 
      "transformative technology", 
      "conventional formalin fixation", 
      "validation", 
      "tissue", 
      "diagnostic histomorphology", 
      "estrogen receptor", 
      "costly freezing", 
      "time", 
      "Histology Preservative", 
      "procurement", 
      "storage", 
      "paraffin", 
      "molecular networks", 
      "NIH R21 funded study", 
      "current requirements", 
      "HER2", 
      "present applications", 
      "clinical validation", 
      "Ki-67", 
      "protein kinase", 
      "complete diagnostic histomorphology", 
      "full diagnostic morphology", 
      "description", 
      "applicants", 
      "molecular profiling", 
      "cases", 
      "formalin fixation", 
      "novel preservation chemistry", 
      "advanced development", 
      "biomarkers", 
      "routine diagnosis", 
      "paraffin blocks", 
      "reverse phase protein microarrays", 
      "subpopulations", 
      "tumor biopsy samples", 
      "therapeutics", 
      "frozen specimens", 
      "progesterone receptor", 
      "new class", 
      "technology", 
      "freezing", 
      "IHC antigens", 
      "novel tissue preservation chemistry", 
      "cancer histology", 
      "organs", 
      "project", 
      "fresh surgical tissue", 
      "objective independent validation", 
      "urgent clinical goal", 
      "nuclear compartment", 
      "additional step", 
      "cost", 
      "standard formalin fixation", 
      "substantial improvement", 
      "diagnostic immunohistochemistry antigens", 
      "BHP", 
      "new non-formalin tissue preservative", 
      "need"
    ], 
    "name": "Implementation of phosphoprotein preservation technology for cancer biospecimens", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.22448.38", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.22448.38", 
          "name": "GEORGE MASON UNIVERSITY", 
          "type": "Organization"
        }, 
        "familyName": "LIOTTA", 
        "givenName": "LANCE ALLEN", 
        "id": "sg:person.01072746376.40", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.01072746376.40", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2631858"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T12:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_16.xml.gz", 
    "startDate": "2011-08-15T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=8504815"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2631858'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2631858'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2631858'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2631858'


 

This table displays all metadata directly associated to this object as RDF triples.

150 TRIPLES      19 PREDICATES      128 URIs      120 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2631858 schema:about anzsrc-for:2206
2 schema:amount Na0ceaa28539c472fbfa43995acab325f
3 schema:description DESCRIPTION (provided by applicant): An urgent clinical goal is to identify molecular networks associated with subpopulations of cancer patients who may respond individually to molecular targeted inhibitors. Current molecular targeted therapeutics is directed at protein kinases and/or their phosphorylated substrates. Therefore, measurement of this new class of phosphoprotein signal pathway epitopes in tumor biopsy samples is crucial for individualizing molecular targeted therapies. Phosphoprotein antigen epitopes are not adequately preserved by formalin fixation and paraffin embedding, and freezing of tissue is very expensive and compromises diagnostic accuracy. We propose the advanced development and clinical validation of an innovative and transformative technology for preserving tissue phosphoproteins and diagnostic histomorphology for clinical cancer molecular profiling. Applying knowledge gained under an NIH R21 funded study, we created a novel tissue preservation chemistry that stabilizes all classes of phosphoproteins, is compatible with paraffin embedding, while maintaining complete diagnostic histomorphology, and fully preserving critical diagnostic immunohistology (IHC) antigens including Estrogen Receptor, Progesterone Receptor, HER2, and Ki-67. These IHC antigens are not preserved by special research fixatives used for tissue RNA preservation. Our new non-formalin tissue preservative, termed Biomarker and Histology Preservative (BHP) can be seamlessly introduced into the current community hospital clinical diagnostic workflow with no additional steps or equipment. At the time of procurement, tissue can be immersed directly in the new fixative and processed into a paraffin block for routine diagnosis, obviating the need for costly freezing during shipping or storage. BHP offers the potential for substantial improvements over conventional formalin fixation. In the present application we propose the blinded clinical validation of our novel preservation chemistry in community hospital settings, utilizing a team of international pathologists for validation. The goal of the project is one-step paraffin block stabilization of all classes of cellular phosphoproteins, diagnostic histomorphology, and diagnostic immunohistochemistry antigens, while at the same time maintaining full diagnostic morphology equivalent or superior to standard formalin fixation. We will collect fresh surgical tissue, under informed consent, covering a broad variety of organs and cancer histology to develop an archive of 150 cases of matched paraffin and frozen specimens. We will measure 100 validated phosphoprotein epitopes spanning membrane, cytoplasmic and nuclear compartments from extracted paraffin sections using Reverse Phase Protein Microarray (RPMA) and Laser Capture Microdissection (LCM) technology. Following objective independent validation by diagnostic pathologists, this transformative technology will be ready for widespread clinical and research use. Adoption of the technology would mean that only one diagnostic paraffin block could be used for all classes of molecular profiling rather than the current requirement for multiple blocks. This would increase diagnostic accuracy while substantially reducing costs.
4 schema:endDate 2016-07-31T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.48336.3a
6 schema:identifier Nd03c6524c4264a75a063605885530815
7 Ne71f403264874fe5833a4cf29368440b
8 schema:inLanguage en
9 schema:keywords BHP
10 HER2
11 Histology Preservative
12 IHC
13 IHC antigens
14 Ki-67
15 NIH R21 funded study
16 Phosphoprotein antigen epitopes
17 additional step
18 adoption
19 advanced development
20 antigen
21 applicants
22 archives
23 biomarkers
24 blinded clinical validation
25 broad variety
26 cancer biospecimens
27 cancer histology
28 cancer patients
29 cases
30 cellular phosphoproteins
31 class
32 clinical cancer molecular profiling
33 clinical diagnostic workflow
34 clinical validation
35 community hospital settings
36 complete diagnostic histomorphology
37 compromise
38 conventional formalin fixation
39 cost
40 costly freezing
41 critical diagnostic immunohistology
42 current community hospital
43 current requirements
44 cytoplasmic
45 description
46 diagnostic accuracy
47 diagnostic histomorphology
48 diagnostic immunohistochemistry antigens
49 diagnostic paraffin block
50 diagnostic pathologist
51 equipment
52 estrogen receptor
53 formalin fixation
54 freezing
55 fresh surgical tissue
56 frozen specimens
57 full diagnostic morphology
58 goal
59 implementation
60 informed consent
61 inhibitors
62 international pathologists
63 knowledge
64 laser capture microdissection
65 measurements
66 membrane
67 molecular networks
68 molecular profiling
69 multiple blocks
70 need
71 new class
72 new non-formalin tissue preservative
73 novel preservation chemistry
74 novel tissue preservation chemistry
75 nuclear compartment
76 objective independent validation
77 one-step paraffin block stabilization
78 organs
79 paraffin
80 paraffin blocks
81 paraffin embedding
82 paraffin sections
83 phosphoprotein
84 phosphoprotein epitopes
85 phosphoprotein preservation technology
86 phosphoprotein signal pathway epitopes
87 phosphorylated substrates
88 present applications
89 procurement
90 progesterone receptor
91 project
92 protein kinase
93 research use
94 reverse phase protein microarrays
95 routine diagnosis
96 same time
97 shipping
98 special research fixatives
99 standard formalin fixation
100 storage
101 subpopulations
102 substantial improvement
103 team
104 technology
105 therapeutics
106 therapy
107 time
108 tissue
109 tissue RNA preservation
110 tissue phosphoproteins
111 transformative technology
112 tumor biopsy samples
113 urgent clinical goal
114 validation
115 schema:name Implementation of phosphoprotein preservation technology for cancer biospecimens
116 schema:recipient N5eb3017e9eb74deb83a9cd4bbf12f8ca
117 sg:person.01072746376.40
118 https://www.grid.ac/institutes/grid.22448.38
119 schema:sameAs https://app.dimensions.ai/details/grant/grant.2631858
120 schema:sdDatePublished 2019-03-07T12:04
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher Nb5b19a3605d74ba5a62fcf4a74e55012
123 schema:startDate 2011-08-15T00:00:00Z
124 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=8504815
125 sgo:license sg:explorer/license/
126 sgo:sdDataset grants
127 rdf:type schema:MonetaryGrant
128 N5eb3017e9eb74deb83a9cd4bbf12f8ca schema:member sg:person.01072746376.40
129 schema:roleName PI
130 rdf:type schema:Role
131 Na0ceaa28539c472fbfa43995acab325f schema:currency USD
132 schema:value 922109
133 rdf:type schema:MonetaryAmount
134 Nb5b19a3605d74ba5a62fcf4a74e55012 schema:name Springer Nature - SN SciGraph project
135 rdf:type schema:Organization
136 Nd03c6524c4264a75a063605885530815 schema:name nih_id
137 schema:value R33CA157403
138 rdf:type schema:PropertyValue
139 Ne71f403264874fe5833a4cf29368440b schema:name dimensions_id
140 schema:value 2631858
141 rdf:type schema:PropertyValue
142 anzsrc-for:2206 schema:inDefinedTermSet anzsrc-for:
143 rdf:type schema:DefinedTerm
144 sg:person.01072746376.40 schema:affiliation https://www.grid.ac/institutes/grid.22448.38
145 schema:familyName LIOTTA
146 schema:givenName LANCE ALLEN
147 rdf:type schema:Person
148 https://www.grid.ac/institutes/grid.22448.38 schema:name GEORGE MASON UNIVERSITY
149 rdf:type schema:Organization
150 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...